Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR975555

—

6fc2dda0-b35d-580e-a361-6f2da0c6ca98

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.500
  • INTERFERON_ALPHA_RESPONSE+0.410
  • PI3K_AKT_MTOR_SIGNALING+0.390
  • PROTEIN_SECRETION+0.380
  • MYC_TARGETS_V1+0.290
  • E2F_TARGETS+0.270
  • MYC_TARGETS_V2+0.260
  • MTORC1_SIGNALING+0.250
  • UNFOLDED_PROTEIN_RESPONSE+0.250
  • G2M_CHECKPOINT+0.240

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
  • ANGIOGENESIS-0.400
  • UV_RESPONSE_DN-0.380
  • COAGULATION-0.310
  • HYPOXIA-0.290
  • MYOGENESIS-0.280
  • TGF_BETA_SIGNALING-0.270
  • IL2_STAT5_SIGNALING-0.250
  • KRAS_SIGNALING_UP-0.250
  • APICAL_SURFACE-0.230

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR6013515
lung-landscapes@6
—cohortA40.892
2TCGA-A8-A06U-01A-11R-A00Z-07
breast-umap@18
—B0.874
3TCGA-18-3419-01A-01R-0980-07
lung-landscapes@6
—cohortSQ10.860
4SRR17866821
colon-landscapes@1
——0.845
52bcd2fcf-9050-4713-aa6b-6cb1419d7ba6
colon-landscapes@1
——0.843
681b828aa-cb06-4790-ba3e-efaa39f4eeef
colon-landscapes@1
——0.840
7MNG277
mng-umap@100
——0.835
8SRR8613729
breast-umap@18
—E0.830
9TCGA-AO-A03O-01A-11R-A00Z-07
breast-umap@18
—C0.824
10SRR1797241
lung-landscapes@6
—cohortSC0.819

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 23 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.500Remibrutinib— uncovered
INTERFERON_ALPHA_RESPONSE0.410Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.390Inavolisib— uncovered
PROTEIN_SECRETION0.380Remibrutinib— uncovered
MYC_TARGETS_V10.290Inavolisib— uncovered
E2F_TARGETS0.270Inavolisib— uncovered
MYC_TARGETS_V20.260Idelalisib— uncovered
MTORC1_SIGNALING0.250Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.250Idelalisib— uncovered
G2M_CHECKPOINT0.240Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.240Inavolisib— uncovered
ADIPOGENESIS0.210Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.180Idelalisib— uncovered
PEROXISOME0.140Idelalisib— uncovered
MITOTIC_SPINDLE0.120Inavolisib— uncovered
P53_PATHWAY0.110Idelalisib— uncovered
SPERMATOGENESIS0.110Inavolisib— uncovered
FATTY_ACID_METABOLISM0.090Inavolisib— uncovered
HEME_METABOLISM0.050Temsirolimus— uncovered
ESTROGEN_RESPONSE_LATE0.040Idelalisib— uncovered